Human Amniotic Epithelial Cells for Asherman's Syndrome

Asherman's Syndrome Clinical Trial

Official title: Safety and Therapeutic Effect of Human Amniotic Epithelial Cells in Severe Refractory Asherman's Syndrome

Status Not yet recruiting

Clinical Trial Summary

This project aims to investigate the safety and effectiveness of human amniotic epithelial cells in the treatment of the severe refractory Asherman's syndrome.

Clinical Trial Description

Asherman's syndrome is a gynecological disorder caused by the destruction of the endometrium due to repeated or aggressive curettages and/or endometritis. As a result, there is a loss of functional endometrium in multiple areas and the uterine cavity is obliterated by intrauterine adhesions, which results in amenorrhea, hypomenorrhea, infertility and recurrent pregnancy loss. Transcervical resection of adhesion (TCRA) is the main treatment for Asherman's syndrome, so far the effect is usually poor in moderate to severe refractory cases.

Human amniotic epithelial cells (hAECs) are derived from human amniotic epithelium. hAECs retain the characteristics approximating to embryonic stem cells. Animal experiments have shown that the endometrial thickness and fertility of mice were significantly improved after intrauterine therapy with amniotic epithelial cells. To further explore the role of hAECs in Asherman's syndrome patients, this project plans to evaluate the safety of hAECs provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd., and find an effective treatment protocol. ;

Related Conditions & MeSH terms

• Asherman's Syndrome
• Syndrome

• NCT number: NCT03223454
• Study type: Interventional
• Source: The Second Affiliated Hospital of Chongqing Medical University
• Contact: Lina Hu
• Phone: 86-23-63693707
• Email: cqhulina@126.com
• Status: Not yet recruiting
• Phase: Phase 1
• Start date: October 2017
• Completion date: March 2021